Prostate biopsy reporting (Histopathological reporting of prostate biopsy samples)
This guide explains what happens to prostate biopsy samples in the laboratory and what the report, including the Gleason score and grade group, can and cannot tell you.
✓ Medically reviewed by a GMC-registered consultant · last reviewed September 2026 · next review September 2027 · how we review
In short
- Prostate biopsy reporting is the microscope examination of cores taken from the prostate, to see whether cancer is present and how the cells look.
- The Gleason score and grade group describe how aggressive the cells appear; grade group 1 is least aggressive and grade group 5 most aggressive.
- A biopsy samples only parts of the prostate, so it can miss or under-grade some cancers, and the picture may be refined by scans or further tests.
- Ask what your grade group means for your options, including active surveillance, and who will explain the report.
A plain-English summary. The detail — including risks and recovery — is below.
At a glance
A general guide. Your specialist will give you advice for your situation.
Shows whether cancer is present in the sampled cores
A prostate biopsy report is the wrong tool for working out whether cancer has spread, which needs scans and your team's assessment.
Your cores are processed, examined and graded, and a second opinion is sometimes sought. This usually takes from one to two weeks.
The result and grade group explained clearly, with time for questions.
Your cores are processed, examined and graded, and a second opinion is sometimes sought. This usually takes from...
Your urology specialist explains the result, including the grade group and what it means, with time for questions.
You may be reassured, kept under review, or have further tests if cancer is still suspected from your PSA or scans.
Your case is discussed by a urology multidisciplinary team, and options such as active surveillance or treatment...
What is prostate biopsy reporting?
A prostate biopsy takes small cores of tissue from the prostate, usually several at once. You do not have the reporting done to you; the samples are sent to a laboratory and examined under the microscope by a histopathologist.
The pathologist checks whether cancer is present in the samples and, if so, how the cells look. Prostate cells are given a pattern from 1 to 5, called the Gleason grade. The Gleason score adds the two most relevant patterns together, for example 3 plus 4. This is now usually translated into a grade group from 1 to 5.
Grade group 1 is the least aggressive and grade group 5 the most aggressive. The higher the grade, the more likely the cancer is to grow and spread outside the prostate. The report also says how many cores contain cancer and how much.
The report tells you about the sampled cores. Because a biopsy samples only parts of the prostate, it can miss or under-grade some cancers, so the picture is sometimes refined by scans, repeat biopsy or later surgery. It does not, by itself, show whether cancer has spread.
Types, options & approaches
There may be different ways to do this. The right approach depends on the clinical question and your circumstances.
What a prostate biopsy can and cannot answer
| Question | How it is answered |
|---|---|
| Is cancer present in the samples? | Microscope examination of the cores (this guide) |
| How aggressive do the cells look? | Gleason score and grade group |
| Has it spread? | Scans and your team's assessment, not the biopsy alone |
A biopsy describes the sampled cores; it can miss or under-grade cancer elsewhere in the prostate.
Preparing for your test
- Remember the reporting is done on your samples, not on you, so there is no fasting or anaesthetic for it.
- When the biopsy is taken, ask when and how you will get the result, and who will explain it.
- Ask whether your case will be discussed by a urology multidisciplinary team.
- Bring someone with you to the appointment where the result is explained.
- Make sure the team has your history, including PSA results and any scans.
- If you are paying privately, ask whether the report and a follow-up appointment are included.
- Write down questions, such as what your grade group means for your options.
What happens
After your prostate biopsy, the cores are preserved, labelled by site and sent to a laboratory. Scientists process them over one or more days, setting them in wax, slicing them thinly, placing them on slides and staining them.
A histopathologist examines the slides under the microscope, looks for cancer in each core, and grades any cancer using the Gleason system and grade groups. Prostate grading can be difficult, so a second opinion is sometimes sought. The report says how many cores are involved and how much.
The pathologist writes a report, which goes to your urology specialist. You are usually given the result at a clinic appointment. Prostate cancer cases are discussed at a multidisciplinary team meeting, where pathology, PSA, scans and your situation are brought together to discuss options with you.
Is this test right for me?
A good consultation should explore whether it's the right choice for you now — including reasons to wait or consider something else.
May not be suitable if…
- A prostate biopsy report is the wrong tool for working out whether cancer has spread, which needs scans and your team's assessment.
- Because it samples only parts of the prostate, it is a poor way to be certain no cancer is present when PSA or scans still suggest it.
- It cannot predict an individual outcome on its own.
Delay or rearrange if…
- Grading is borderline and a second opinion is being sought.
- Key information such as PSA or MRI results is missing, as these are interpreted together.
- The result does not fit the clinical picture and further scans or a repeat biopsy are being arranged.
Alternatives to discuss
- Active surveillance rather than immediate treatment for some lower-grade cancers.
- Further imaging, such as MRI, or a repeat biopsy if the picture is unclear.
- A second opinion on the grading for a borderline result.
Before you decide
Use this as a shared-decision checklist. The aim is not just “can this be done?”, but whether it is right for you, now, with the risks and alternatives clearly understood.
What matters most to me?
Think about symptoms, daily life, work, caring responsibilities, sport, fertility, travel, appearance and anxiety — the right choice depends on your priorities, not just the medical facts.
What are all my options?
Ask about waiting, monitoring, medicines, rehabilitation, a smaller or larger procedure, a different test, NHS referral, or a second opinion where that would help.
What would make me pause?
Active infection, pregnancy, unstable medical problems, smoking, medicines that increase bleeding, poor support at home, or feeling pressured are all reasons to slow down and get tailored advice.
What happens if I do nothing today?
For some problems, waiting is safe; for others, delay can make treatment harder. A good consultation should explain the trade-off in plain English.
Benefits
- Shows whether cancer is present in the sampled cores
- Describes how aggressive the cells look, using the grade group
- Says how many cores are involved and how much
- Helps decide between options such as monitoring and treatment
- Provides a written report a urology team can review
- Forms the basis for planning alongside PSA and scans
Risks & complications
- Waiting and worry while the report is prepared
- A result that needs careful explanation of grade and options
- Uncertainty because the biopsy samples only parts of the prostate
- A borderline grade that needs a second opinion
- An under-graded cancer, found to be more aggressive on later surgery
- A negative biopsy when cancer is still suspected, needing further tests
- A diagnosis or grade that changes after specialist review
- An unusual prostate tumour that is difficult to classify
The main limitations are that the biopsy samples only parts of the prostate, so it can miss cancer or under-grade it, and that the grade can change on later surgery. The report does not show whether cancer has spread. Ask what your grade group means for your options, whether your case has been to a urology team, and whether scans or a repeat biopsy are needed if the result does not fit your PSA.
Published figures to discuss
This is a diagnostic interpretation of tissue already removed, so it does not carry the procedure's own complication rates. The real uncertainties are that grading is partly subjective and can differ between pathologists, that a biopsy samples only part of the gland and can under-grade or miss cancer, and that the grade may change on later surgery. These vary by case and setting, so this guide does not quote single percentages.
| Figure | Reported range | How to interpret it | Source / confidence |
|---|---|---|---|
| Cancer missed by biopsy | Recognised sampling limitation | MRI-targeted and systematic cores reduce but do not remove the chance of missing clinically significant cancer. | Guide sourcesClinical context |
| Grade group changes after prostatectomy | Recognised | The whole gland can show higher or lower grade than needle samples. | Guide sourcesClinical context |
| Low-risk cancer overtreated | Important management issue | Active surveillance may be appropriate when grade, PSA, MRI and volume suggest low risk. | NHS — Prostate cancernhs.ukSource-linked context |
| Report terms misunderstood | Common | Gleason score, grade group, core involvement and perineural invasion should be explained with the MDT plan. | Guide sourcesClinical context |
These are literature figures, not a personalised prediction. Your own risks and likely benefits depend on your circumstances, your health, and how your care is carried out and followed up.
What happens afterwards
There is no physical recovery from the reporting itself, because it is done on your samples in a laboratory. Afterwards is about waiting for the report, having it explained, and discussing your options.
- Feeling anxious while you wait for the result
- Being given the result at a clinic rather than by phone
- Hearing that your grade group guides, but does not dictate, your options
- Being told scans or a repeat biopsy may be needed
- Learning that active surveillance is an option for some lower-grade cancers
Aftercare
- Note when results are expected and chase them if they are late.
- Bring someone with you and ask for the result to be explained clearly.
- Ask what your grade group and number of involved cores mean for your options.
- Ask whether active surveillance is suitable, if your cancer is lower grade.
- Check whether your case has been discussed by a urology multidisciplinary team.
- Find out who your point of contact is, such as a specialist nurse.
- Ask for written information and a copy of your report if you would like one.
- Date of the results clinic written down
- Someone arranged to come with you
- Questions ready about grade group and options
- Question ready: is active surveillance suitable?
- Name of your specialist nurse or contact
- A way to access reputable support
- Plan for who chases the result if it is late
⚠ Get urgent help if…
- Heavy bleeding, or inability to pass urine, after the biopsy
- Fever, chills or feeling very unwell, which can signal infection after a prostate biopsy
- Severe pain or significant blood in the urine, semen or stools that does not settle
- Not hearing your result by the date you were given
- Feeling overwhelmed, very low or unable to cope while waiting
- Being unsure who to contact about your result or symptoms
Who to contact: your clinician, clinic or test provider first (keep their number to hand). For urgent advice when you can't reach them, call NHS 111. In an emergency, call 999.
General guidance — it doesn't replace the specific advice your specialist gives you.
Results & realistic expectations
A good outcome from this test is a clear report that says whether cancer is present and, if so, gives a grade group and the amount of cancer, so your options can be discussed sensibly. For many men with lower-grade cancer, careful monitoring (active surveillance) is a reasonable option.
The grade group is a strong guide to how a cancer may behave, but it describes groups of men, not a fixed prediction. Because a biopsy samples only parts of the prostate, the grade can be refined on scans or later surgery, and a negative biopsy does not always rule cancer out. Your urology team interprets the report alongside your PSA and scans.
A prostate biopsy report describes the sampled cores at the time of the biopsy. The grade can change on later surgery, and prostate cancer can behave differently over time, so men on active surveillance are monitored with PSA, scans and sometimes repeat biopsies. Plans are reviewed as more information becomes available rather than fixed by a single report.
Related tests, treatments or support
Prostate biopsy reporting usually goes hand in hand with PSA blood tests and prostate scans, such as MRI. A urology multidisciplinary team brings the pathology, PSA and scans together to discuss options, which may range from active surveillance to treatment.
Follow-up & long-term care
Your urology specialist, often with a specialist nurse, is responsible for explaining the result and discussing your options. Expect a cancer case to be discussed by a urology multidisciplinary team. Ask how and when you will hear, what your grade group means for you, and who to contact in the meantime.
- If you are on active surveillance, attend regular PSA tests and reviews.
- Have any further scans or repeat biopsies as advised.
- Report new urinary, bowel or other symptoms to your team.
- Ask what changes would prompt a move from monitoring to treatment.
Repeat, follow-on and what comes next
- The grade may change on the larger sample if surgery is later done.
- A repeat biopsy or further scans are sometimes needed when the result does not fit the PSA or MRI.
- Specialist second opinions are common for prostate grading and can change the grade group.
Ask what happens if the result is unclear or needs repeating, and what is included if further tests or follow-up are needed.
What good aftercare looks like
- The result and grade group explained clearly, with time for questions.
- A named contact, such as a specialist nurse, to support you.
- A clear plan, whether active surveillance with monitoring or treatment, agreed by a urology team.
- Written information and access to reputable support while you decide.
What affects the cost
Costs vary a great deal between people and providers, and we don't publish prices. What matters is understanding what drives the cost and making sure your quote is complete. The main things that affect it:
- Whether the laboratory report is included in the price of the biopsy
- The number of cores examined
- Whether extra stains or tests are needed to grade the cancer
- Whether a specialist uropathologist or a second opinion is involved
- Whether a results appointment and team discussion are included
- Whether onward scans or monitoring are arranged
- Confirmation that the laboratory report is included, not just the biopsy
- The fee for any extra stains or tests
- The cost of a second opinion if you want one
- Whether a results appointment to explain the report is included
- What happens, and what it costs, if a repeat biopsy is needed
- How and when you will receive your result
On the NHS? Prostate biopsy reporting is a core NHS service when the samples are taken on the NHS; private reporting may add speed, choice or a second opinion, but there are no prices on this page.
You're entitled to your total cost in writing — including reports, follow-up and what happens if the result is inconclusive — before you decide.
Consent traps and marketing red flags
These are not small details. They are often where patients lose choice, time to reflect, or realistic expectations.
Consent traps
- Being told a grade without an explanation of what it means for your options.
- Assuming a negative biopsy completely rules out cancer.
- Not being told that active surveillance is an option for some lower-grade cancers.
- Not being offered or told about a second opinion for borderline grading.
Marketing red flags
- Promising certainty from a single biopsy when prostate sampling can miss cancer.
- Pushing immediate treatment without discussing active surveillance where appropriate.
- Implying a private report is more accurate than NHS reporting.
- Discouraging a second opinion on a borderline grade.
Choosing a specialist safely
- Check the specialist is on the GMC Specialist Register for this area.
- Make sure they work at a CQC-registered service, and look for membership of the relevant Royal College or professional body.
- You're entitled to time to consider and to have your questions answered before you agree — the specialist who looks after you should explain it, not a salesperson.
- Be wary of pressure: time-limited offers or deposits taken before you've had time to think are red flags, not bargains.
- You're entitled to your total cost in writing — including any follow-up — before you decide.
Questions to ask your medical professional
Take this to your consultation. A good specialist will welcome every one of these.
- Is cancer present, and what is my grade group?
- How many cores contain cancer, and how much?
- What does my grade group mean for my options, including active surveillance?
- Has my case been discussed by a urology multidisciplinary team?
- Do I need scans or a repeat biopsy if the result does not fit my PSA?
- What would change the plan from monitoring to treatment?
- Are you on the GMC Specialist Register for this area, and which Royal College or professional body are you a member of?
- Will you be the specialist who carries out my test, and who looks after me afterwards?
- What are the risks for someone like me, and how often do your own patients have a problem or need it repeated or redone?
- What does a realistic result look like — and what can this test not achieve?
- What are my options, including waiting, doing nothing for now, or choosing a different approach?
- Can I have written information, results and aftercare instructions in a format I can use, including any accessibility or communication support I need?
- What is the total cost in writing, including any follow-ups, and how much time do I have to decide?
Frequently asked questions
What is a Gleason score and a grade group?
Does cancer in my biopsy mean I need treatment straight away?
How long do results take?
Can a biopsy miss cancer?
Does the biopsy show whether the cancer has spread?
Is this done on the NHS?
Find a verified specialist for prostate biopsy reporting
Every consultant is GMC-checked and independently reviewed. Search by postcode and distance, or switch to a map. Ordered by rating, relevance and recency — never by who pays.
No verified consultants list this procedure yet — browse the full directory.
How we made this page
Medically reviewed by a GMC-registered consultant. Written in plain English, checked against NHS, NICE, GMC and relevant Royal College / specialist-society guidance, and kept under review. No clinic paid to appear on this page, and we publish no pricing. This is general information to help you prepare — it is not a substitute for advice from your own clinician. How we review our guides →
Source hierarchy: UK regulator and NHS/NICE guidance first, then relevant Royal College or specialist-society guidance, then peer-reviewed evidence for procedure-specific figures where available.
Sources & standards: Prostate Cancer UK — What do my test results mean? Cancer Research UK — Grade groups for prostate cancer Macmillan Cancer Support — Staging and grading of prostate cancer NHS — Prostate cancer Prostate Cancer UK — Prostate biopsy Royal College of Pathologists — What is a biopsy?
Reviews reflect patients' experience of care, not clinical outcomes. For procedure volumes and outcome data see PHIN.
Last medically reviewed 2026-09-21. Spotted something wrong or out of date? Report an error in this guide.
Related guides: Tumour and cancer diagnosis from a biopsy · Cancer staging and grading report · Excised lesion and specimen analysis · Breast biopsy reporting · Biopsy analysis (tissue diagnosis)